GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MariMed Inc (OTCPK:MRMD) » Definitions » Debt-to-Equity

MariMed (MariMed) Debt-to-Equity : 1.12 (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is MariMed Debt-to-Equity?

MariMed's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.9 Mil. MariMed's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $76.2 Mil. MariMed's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $71.6 Mil. MariMed's debt to equity for the quarter that ended in Dec. 2023 was 1.12.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for MariMed's Debt-to-Equity or its related term are showing as below:

MRMD' s Debt-to-Equity Range Over the Past 10 Years
Min: -5.72   Med: 0.63   Max: 6.21
Current: 1.12

During the past 13 years, the highest Debt-to-Equity Ratio of MariMed was 6.21. The lowest was -5.72. And the median was 0.63.

MRMD's Debt-to-Equity is ranked worse than
88.08% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs MRMD: 1.12

MariMed Debt-to-Equity Historical Data

The historical data trend for MariMed's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MariMed Debt-to-Equity Chart

MariMed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.21 4.91 0.64 0.61 1.12

MariMed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.61 0.97 0.79 0.79 1.12

Competitive Comparison of MariMed's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MariMed's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MariMed's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where MariMed's Debt-to-Equity falls into.



MariMed Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

MariMed's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

MariMed's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MariMed  (OTCPK:MRMD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


MariMed Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of MariMed's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


MariMed (MariMed) Business Description

Traded in Other Exchanges
Address
10 Oceana Way, Floor 2, Norwood, MA, USA, 02062
MariMed Inc is a multi-state operator in the United States cannabis industry. It develops, operates, manages, and optimizes regulatory-compliant facilities for the cultivation, production, and dispensing of medical and adult-use cannabis. MariMed also licenses its proprietary brands of cannabis products along with other top brands in domestic markets Sources of revenue are comprised of Product sales (retail and wholesale), Real estate rental income, Supply procurement, Management fees, and Licensing fees.
Executives
Jon R Levine 10 percent owner C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
Timothy Shaw officer: Chief Operating Officer C/O MARIMED INC, 10 OCEANA WAY, NORWOOD MA 02062
Kathleen Tucker director C/O 10 OCEANA WAY, 2ND FLOOR, NORWOOD MA 02062
Susan M. Villare officer: Chief Financial Officer C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
Selhub Eva M.d. director C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
David R Allen director C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
Thomas Kidrin director 11 ROYAL ROAD, BROOKLINE MA 02445
Edward J Gildea director C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
Jay Coleman director 310 EAST 46TH ST. APT 9 F, NEW YORK NY 10017
Robert N Fireman director 145 ROSEMARY ST. SUITE H-2, NEEDHAM MA 02494
Worlds.com, Inc. director, 10 percent owner, officer: PRESIDENT, CEO, other: TREASURER, SECRETARY 11 ROYAL ROAD, BROOKLINE MA 02445
Christopher John Ryan officer: CFO, VICE PRESIDENT 11 ROYAL RD, BROOKLINE MA 02445